CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury

What Was Tested

The paper reports a study of CGRP (Calcitonin Gene-Related Peptide) in the context of migraine, published as a clinical trial.

To ascertain whether intravenous infusion of calcitonin gene-related peptide (CGRP) can induce migraine-like headache in people with persistent post-traumatic headache attributed to mild traumatic brain injury (TBI) and no pre-existing migraine.

Who Took Part

The age groups tagged for this paper are adults, both men and women.

Eligible participants were aged 18 to 65 years and had a known history of persistent post-traumatic headache attributed to mild TBI for ≥ 12 months.

How the Study Was Run

The researchers set it up as an open-label study.

Everyone knew when CGRP (Calcitonin Gene-Related Peptide) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

A non-randomized, single-arm, open-label study at a single site in Denmark.

A headache diary was used to collect outcome data until 12 h after the start of CGRP infusion.

The primary end point was the incidence of migraine-like headache during 12-hour observational period.

What Was Measured

Topics PubMed links to this paper include Brain Concussion, Calcitonin Gene-Related Peptide, Headache, Migraine Disorders, Post-Traumatic Headache and Tension-Type Headache.

The authors tagged it with the keywords CGRP, Pathophysiology and Trigeminovascular System.

What This Means in Plain Language

The paper is an open-label study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (The journal of headache and pain), a journal based in England.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.